Authors/Disclosures
|
Dawn W. Langdon, PhD
(Royal Holloway)
|
Prof. Langdon has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck. Prof. Langdon has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. The institution of Prof. Langdon has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celgene. Prof. Langdon has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Celgene. Prof. Langdon has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Prof. Langdon has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer. The institution of Prof. Langdon has received research support from Merck. The institution of Prof. Langdon has received research support from Novartis. The institution of Prof. Langdon has received research support from MS Society (UK). The institution of Prof. Langdon has received research support from Multiple Sclerosis Trust (UK). |
|
Christina Mijalski, MD, MPH
(Stanford Stroke Center)
|
Dr. Mijalski has nothing to disclose. |
|
Eva-Maria Wicklein, MD
(Bayer AG)
|
Dr. Wicklein has received personal compensation for serving as an employee of Bayer AG. |
|
Douglas M. Wallace, MD
(Miami VA HealthCare System)
|
No disclosure on file |
|
|
No disclosure on file |
|
|
No disclosure on file |